Crohn's suffer since 12/2011, Fecal transplant recipient (Thanks Mayo Clinic!), providing the latest news and research in Crohn's (Remission since June 2012)
Joined October 2012
- Tweets4.3K
- Following287
- Followers682
- Likes73
Crohn's Zone retweeted
The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
The approval is based on results from the ATOMIC clinical trial led by Mayo Clinic. Learn more: mayocl.in/4yfvUM2
Crohn's Zone retweeted
Prof Florian Rieder: (OP-003) PALI-2108 (PDE4 inhibitor) for fibrostenosing Crohn’s was safe and possibly effective (n=5) with favorable PK and target engagement #uegweek2026
Crohn's Zone retweeted
Earlier this week I said the most important development in IBD of the last decade was... biosimilars.
Here's the other half of the story.
20 new molecules in Phase 2 or later. Eight targets, plus dual-target combinations. If their trials succeed, up to six could be approved in Europe by 2031.
TL1A is entering phase 3 readout time. Oral IL-23R blockade is in Phase 3. Co-formulated combination therapy is in Phase 3.
Look at phase 2 and the pipeline is stacked. There’s even an anti-fibrotic for stricturing Crohn's.
Biosimilars bought the headroom. This is what fills it. And it is very exciting.
The limiting step now isn't the science. It's trial delivery: opening sites, finding eligible patients, research teams fitting studies around full clinical jobs.
The good news? That's the part we can fix. Faster set-up, and every eligible patient offered a trial. That's how 2033 becomes 2031.
Honestly, this is extraordinary.
Crohn's Zone retweeted
A potential new option for one of Crohn’s disease’s toughest complications.
New phase 3 FUZION data explored guselkumab for perianal fistulizing Crohn’s disease—with results that GEN Expert Pick Uma Mahadevan, MD, called notable: gastroendonews.com/a/iz0BAA/… #IBD
Crohn's Zone retweeted
Very timely discussion on @mondaynightibd.
Exciting new monoclonal antibodies are getting closer to entering the IBD treatment armamentarium: anti TL1A therapies.
Several molecules are now competing in this race, with subtle but potentially important molecular differences in how they interact with TL1A and the TL1A DR3 pathway.
So far, I would not call the efficacy results earthshattering. The bigger questions may be what makes this pathway truly different:
🔬 Can TL1A inhibition make a clinically meaningful dent in intestinal fibrosis, rather than simply control inflammation?
🧬 Could its future lie in combination therapy, as Spyre is exploring by combining TL1A blockade with other pathways?
And one question I find particularly intriguing:
💭 Could TL1A inhibition eventually have a role in collagenous colitis, given the biology of mucosal inflammation and collagen deposition?
The TL1A story may ultimately be less about another effective biologic and more about whether it can do something our current therapies cannot.
Check out my LinkedIn post
linkedin.com/posts/ibd-libra…
#IBD #CrohnsDisease #UlcerativeColitis #TL1A
@MondayNightIBD @DCharabaty @Bealoquebea @IBDimmunology @ShomronH @RPanaccione
18/ #MondayNightIBD
🔥Anti-TL1A-Exciting 🆕 MOA
🧘🏽♀️RELIEVE-UCCD/DUVA
🏹ARTEMIS-UC & 🎻APPOLO-CD/TULI
🌻TUSCANY(UC)/AFIM
✅Meaningful induction efficacy
✅Efficacy maintained at 1yr
✅👌🏽 Safety, no class 🚩
✅Low immunogenicity
💬What are you mostly excited about for this MOA?
Crohn's Zone retweeted
This thread is a great summary of what we know so far for the anti-TL1A antibodies for the treatment of #IBD
Once we see the phase 3 data on these molecules we’ll have a better sense of how they fit in the algorithm
5/#MondayNightIBD
RELIEVE UCCD 📊Wk 14 outcomes in #Crohns
🔦Endo Response (≥50% ↓ SES-CD)
48% (900mg)/ 26% (450mg) DUVA vs 13% PBO
Δ33% PP >0.99 | Δ13% PP 0.94
🩺Clinical Remission (PRO2)
37%/37% DUVA vs 26% PBO
Δ10% PP 0.87 (both doses)
Crohn's Zone retweeted
Important messages by @berinsj during @AmCollegeGastro Midwest PG Course. 6 Principles of acute severe ulcerative colitis management.
🕯️Colectomy rate is still bothersome in ASUC
🕯️JAKi may help produce a meaningful dent in colectomy rate
🕯️Never forget to address mental health early
Patient education is critical
Crohn's Zone retweeted
In February 2024, Propel a Cure awarded a 2-year, $100,000 Trailblazer Grant to Promakhos Therapeutics to advance an innovative approach to treating #Crohns disease. Promakhos is developing an oral, non-immunosuppressive precision therapy designed to restore a natural biological signal that appears to be missing in Crohn’s.
With support from Propel a Cure and other funding sources, the team has made significant progress. In preclinical studies, the therapy has shown promising results by promoting intestinal healing, reducing bowel inflammation, improving the gut microbiome, and helping clear invasive microbes. The candidate drug also has a distinct mechanism of action that works upstream of current therapies and is paired with a biomarker strategy to help identify patients most likely to benefit.
In Spring 2026, Promakhos co-founder and CEO @Katerina_Hatzi received the prestigious Harvard President’s Innovation Challenge Award, recognizing groundbreaking solutions to global challenges.
The next milestone is advancing this promising therapy into human safety studies, bringing it one step closer to patients living with Crohn’s disease and others affected by inflammatory diseases.
Crohn's Zone retweeted
“Microbial richness and diversity were increased, and community structure was altered with the intervention”
healthday.com/healthpro-news…
Crohn's Zone retweeted
Fecal microbiota transplantation showed promise in slowing or reducing cognitive impairment in aging dogs and may be worth considering as an adjunct therapy in these cases. 🐕 Open access article: jav.ma/fmt1
Crohn's Zone retweeted
An iPhone compatible endoscope with a diameter of 5.2mm and a 3.2mm working channel
Crohn's Zone retweeted
At @WoolstonLabNEU, a recipient of a Propel a Cure grant in partnership with the Mendez Family Foundation, animal experiments examining the long-term effects of modulated #sulfide on gastrointestinal physiology are continuing.
Researchers hope these studies will reveal to what extent raising sulfide levels in otherwise healthy mice contributes to the onset of inflammation, providing new insights into the role of microbial hydrogen sulfide in #IBD.
The team has also reached an exciting publication milestone by submitting its first manuscript about the engineered bacterial strains used in the project to a scientific journal, and has received favorable comments from peer reviewers.
They are now working on incorporating the feedback into a revised paper and are hopeful the published paper will be available online soon.
Northeastern University recently produced this 60-second video clip explaining this exciting project. To view, please click here: m.youtube.com/shorts/HRvwIQv…
Crohn's Zone retweeted
Patient portal messaging volume in the US increased by more than 150% between 2020 and 2025, with messages per patient rising from 0.99 to 2.50 per year; highest usage occurred in urban settings and among patients with low social vulnerability.
ja.ma/4b8WzS9
Crohn's Zone retweeted
A Milestone Year for IBD Research 🎉
Our two scientific journals just hit new highs in their "impact factor" — a measure of how widely research is cited and used by the scientific community, signaling its influence on the field.
🔹 Inflammatory Bowel Diseases®️: 5.5 (up 28% from last year)
🔹 Crohn's & Colitis 360: 3.0 (up 15% from last year)
The takeaway: research published in our journals is reaching more doctors and scientists than ever — accelerating progress toward better treatments and cures for Crohn's disease and ulcerative colitis.
Thank you to our editors, reviewers, and researchers for driving this work forward.
Crohn's Zone retweeted
🎯 Q3 2026 Psychedelic Drug Development Bullseye Charts: A comprehensive overview of the psychedelic pipeline across two views.
You can explore the charts on our website, where you can also retrieve a high-quality PDF copy: psychedelicalpha.com/news/q3…
Crohn's Zone retweeted
🌟 New Chapter Spotlight: Dr. John Damianos
After completing fellowship with Mayo Clinic Gastroenterology & Hepatology, John is joining the faculty at Cleveland Clinic.
Known for his exceptional clinical expertise, scholarly curiosity, and dedication to teaching, John has distinguished himself as a thoughtful clinician, accomplished researcher, and inspiring educator. Colleagues praised his clinical judgment, communication skills, commitment to patients, and ability to make complex topics engaging and accessible.
Congratulations, John! We are excited to see all you will accomplish at Cleveland Clinic. 🎉
#GIH #MedEd #Gastroenterology #NewChapterSpotlight
Crohn's Zone retweeted
The brain continues to make new neurons throughout life.
It is never too late to learn a new skill.
Crohn's Zone retweeted
There is nothing quite like the joy of seeing healing.
Behind every healed intestine is a patient who may finally be sleeping through the night, returning to work, enjoying meals, and living life without constant fear of a flare.
This is why we strive for more than symptom relief. We strive for deep healing.
Every healed mucosa represents renewed hope.
IBD Library™
Crohn's Zone retweeted
The Twitterless Prof Sid Singh discussing medical therapy of fistulizing Crohn’s disease #SidSingh #AOCC2026 @MayoClinicGIHep Define, drainage, antibiotics, medical therapy. Use TOpClass for characterizing fistula
